Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1281-1300 of 3,900 trials

Eosinophilic Granulomatosis with Polyangiitis: Mepolizumab Treatment

We are studying how mepolizumab affects the nasal microbiome and immune response in patients with eGPA. This research may help understand its impact on local inflammation in the ENT area.

Eosinophilic Granulomatosis with Polyangiitis (eGPA)>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOtolaryngology

Acute Myeloid Leukemia: Vyxeos and Clofarabine Study

We are testing a new combination treatment for children with relapsed or refractory AML to find the best dose and evaluate its safety. The study aims to see if this treatment can help achieve remission and support future stem cell transplants.

Acute Myeloid LeukemiaSafety phase (I)No PlaceboStandard MedicinesOncologyPediatrics

Endometrial Cancer: New Treatment Combinations

We are studying whether a new combination of Trastuzumab Deruxtecan with Rilvegostomig or Pembrolizumab is more effective than standard chemotherapy for patients with advanced or recurrent HER2-expressing endometrial cancer.

Endometrial CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Biliary Tract Cancer: T-DXd and Rilvegostomig Study

We are studying a new treatment combination for patients with advanced HER2-expressing biliary tract cancer. The goal is to see if it helps improve survival compared to standard care options.

Advanced HER2-expressing Biliary Tract Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Colorectal Cancer: NILK-2301 Antibody Study

We are testing a new antibody treatment for patients with colorectal cancer to see how safe it is and how well it works. This study aims to gather important information for future treatments.

Locally Advanced or Metastatic Low Tumor Volume Colorectal Cancer>2 yearsSafety phase (I)GastroenterologyOncology

Dupilumab for Chronic Rhinosinusitis with Nasal Polyps

We are studying how dupilumab affects ear symptoms and hearing in patients with chronic rhinosinusitis and eosinophilic otitis media. This research aims to improve understanding of treatment benefits for these conditions.

Chronic Rhinosinusitis with Nasal PolypsEosinophilic Otitis Media>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyOtolaryngology

CRSwNP: Predicting Response to Mepolizumab

We are studying biomarkers to see if they can help predict how well patients with CRSwNP respond to the treatment mepolizumab. This research aims to improve personalized treatment options for these patients.

Chronic Rhinosinusitis with Nasal Polyps≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyOtolaryngology

Castrate-Resistant Prostate Cancer: Acetylsalicylic Acid and Atorvastatin Study

We are investigating whether acetylsalicylic acid and atorvastatin can improve survival in patients with castrate-resistant prostate cancer. The study will also look at other health impacts and safety of these medications.

Castration-Resistant Prostate CancerConfirmation phase (III)No PlaceboInvestigational MedicinesOncologyUrology

Advanced Colon Cancer: Preoperative Chemotherapy Study

We are investigating whether chemotherapy before surgery is more effective than surgery followed by additional treatment for advanced colon cancer. This trial aims to improve treatment strategies for patients.

Colon Cancer (Stage T3-4)>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Polymyalgia Rheumatica: Secukinumab Safety Study

We are evaluating the long-term safety of secukinumab for individuals with polymyalgia rheumatica. This study will help us understand any potential side effects associated with this treatment.

Polymyalgia Rheumatica>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

Postmenopausal Bone Health: Everolimus and Exercise Study

We are investigating whether everolimus, exercise, or both can improve bone formation in healthy postmenopausal women. This study aims to help prevent bone loss and support skeletal health.

Healthy Participants3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyInternal MedicineOrthopedics and Traumatology

Breast Cancer Treatment for Women 70+: Radiation vs. Hormone Therapy

We are comparing radiation therapy and hormone therapy for older women with early-stage luminal A-like breast cancer. The goal is to see which treatment better controls cancer and improves quality of life.

Breast Cancer1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Childhood Absence Epilepsy: Brivaracetam Safety Study

We are studying the long-term safety of brivaracetam in children and young adults with childhood or juvenile absence epilepsy. This research aims to understand how well the medication is tolerated over time.

Childhood Absence EpilepsyJuvenile Absence Epilepsy>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPediatrics

Atopic Dermatitis: Amlitelimab Treatment Study

We are studying two dosing schedules of amlitelimab for people aged 12 and older with moderate-to-severe atopic dermatitis. The goal is to see if it helps maintain treatment response compared to stopping treatment.

Atopic Dermatitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Advanced Biliary Cancer: Personalized Targeted Therapy

We are studying whether a new personalized treatment can help patients with advanced biliary cancer live longer without disease progression compared to standard care. This trial also examines the quality of life and safety of the new therapies.

Advanced Biliary Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicineOncology

Lymphoblastic Lymphoma: New Treatment Protocol for Kids

We are studying whether changing medications during treatment can help reduce relapses in the brain for children and adolescents with lymphoblastic lymphoma. This trial aims to improve survival rates and treatment outcomes compared to standard approaches.

Lymphoblastic Lymphoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

COVID-19 Treatment: Anti-Coronavirus Immunoglobulin Study

We are testing a new immunoglobulin treatment for adults recently diagnosed with COVID-19 to see if it improves health outcomes compared to a placebo. This study aims to understand its safety and effectiveness alongside standard care.

COVID-19≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteInfectious DiseasesInternal Medicine

ROS1-Positive Lung Cancer: REPotrectinib Study

We are testing a new treatment for patients with ROS1-positive non-small cell lung cancer and active brain metastasis. The study aims to see how well it works in shrinking brain tumors and to assess its safety.

ROS1-positive Non-Small Cell Lung Cancer with Brain Metastasis1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurologyOncology

Anakinra for Persistent Respiratory Symptoms After COVID-19

We are studying whether anakinra can help patients with ongoing respiratory issues after COVID-19 improve their symptoms and immune function. This trial is for those experiencing long-term effects of the virus.

Post-Acute COVID Syndrome≤3 monthsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesInfectious DiseasesInternal MedicinePulmonology

Bipolar Depression: Esketamine Nasal Spray

We are studying the safety and effectiveness of esketamine nasal spray for people with treatment-resistant bipolar depression. This trial aims to gather important information that could lead to future studies.

Bipolar Disorder - Depressive Episode≤3 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPsychiatry